Alvotech Ordinary Shares ALVO

Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.

• GlobeNewswire Inc. 3 jul

  Viðskipti stjórnenda og tengdra aðila

  Alvotech secured a $75 million term loan facility maturing December 31, 2027, led by GoldenTree Asset Management. This follows a recent $165 million equity raise, further strengthening the company's cash position and liquidity.

  

• GlobeNewswire Inc. 3 jul

  Transactions of Managers and Closely Associated Persons

  Alvotech secured a $75 million term loan facility maturing December 31, 2027, led by GoldenTree Asset Management. This follows a recent $165 million equity raise, further strengthening the company's cash position and liquidity.

  

• GlobeNewswire Inc. 22 jun

  Viðskipti stjórnenda og tengdra aðila

  Alvotech successfully closed a public offering raising $165 million in aggregate, with underwriters fully exercising their option to purchase additional shares. The offering included a concurrent private placement where Celtic Lux Holdings purchased 10.133 million shares at $3.75 per share on June 16, 2026.

  

• GlobeNewswire Inc. 22 jun

  Transactions of Managers and Closely Associated Persons

  Alvotech closed a public offering raising $165 million in aggregate proceeds, with underwriters fully exercising their option to purchase additional shares. The offering included a concurrent private placement where Celtic Lux Holdings acquired 10,133,333 shares at $3.75 per share.

  

• GlobeNewswire Inc. 15 jun

  Alvotech tilkynnir um verð og úthlutun hlutabréfa að andvirði um 152 milljónir dollara í útboði í Bandaríkjunum og lokuðu útboði til fagfjárfesta á Evrópska efnahagssvæðinu

  Alvotech (NASDAQ: ALVO) announced a $152 million share offering, comprising an $85 million public offering in the US at $3.75 per share and a $67 million private placement to institutional investors in the EEA. The company plans to use proceeds for biosimilar drug development, working capital, and operational expenses. BofA Securities, Jefferies, and Evercore ISI are joint underwriters.